Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0393754 (
HSA
)
2,996
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vapreotide (RC-160), an octapeptide analog of somatostatin, has a high affinity for somatostatin receptor subtypes SSTR2 and
SSTR5
. Vapreotide binds differently to the tumors of the breast, ovary, exocrine pancreas, prostate and colon, than octreotide another octapeptide analog of somatostatin. Vapreotide was labeled with Tc-99m, a radionuclide highly suitable for scintigraphic imaging. The labeling procedure was simple, produced >70% yields and could be applicable to label other peptides containing a cystine bridge. HPLC analysis showed that the tracer was stable when Tc-99m-RC-160 was challenged with 100 fold molar excess DTPA (diethylenetriaminepentaacetic acid),
HSA
(human serum albumin) or cysteine and incubated at 37 degrees C for 4 h. HPLC analysis of urine samples obtained from mice that received Tc-99m-RC-160 showed that the preparation was stable in vivo. Rat brain cortex membrane receptor displacement assays showed that the Kd values for Tc-99m-RC-160 (71x10(-9) M) and Tc-99m-octreotide (86x10(-9) M) (Sandostatin(R)) were in nM range, and were similar to that for I-125-RC-160 (46x10(-9) M). High binding affinity of Tc-99m-RC-160 for human breast tumor cells SKBR-3 was also observed. These results suggest that Tc-99m-RC-160 is worthy of evaluation as an agent for scintigraphic imaging of tumors rich in somatostatin receptor subtypes SSTR2 and
SSTR5
.
...
PMID:Vapreotide labeled with Tc-99m for imaging tumors. 2154 33